Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control and contain pleiotropic actions on kidney injury, albuminuria and vascular inflammation especially in animal models. We plan to evaluate the efficacy of potent DPP4-inhibitors (gemigliptin) in response to these aspects in diabetic nephropathy patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bangkok Metropolitan Administration Medical College and Vajira Hospital

Criteria

Inclusion Criteria:

• Patients with CKD stage 1-3 (eGFR 15-60 ml/min/1.73mL)

• Non-insulin dependent diabetes mellitus , blood glucose level 30-250 mg/dL

• Had clinical features compatible with diabetic nephropathy (urine micro albuminuria > 30 g/g creatinine or has evidence of diabetic retinopathy

Exclusion Criteria:

• History of allergy to DPP4-inhibitor

• Concurrent infectious disease

• Inflammatory diseases

• Post kidney transplantation

• Receiving cinacalcet, bisphosphonate ,previously treated with DPP4-Inhibitors and sodium-glucose cotransporter-2 inhibitor (SGLT2-i).